CRISPR Therapeutics names SVP Finance Andrew Silver as CFO; Raju Prasad resigns
CRISPR Therapeutics promoted Andrew J. Silver, its SVP of Finance, to Chief Financial Officer effective immediately on October 19, 2026. CFO Raju Prasad resigned the same day to pursue external opportunities and is expected to remain employed until on or before November 30, 2026. The filing says Dr. Prasad's resignation was not due to any disagreement with the company on financial or accounting matters.
Key points
- Andrew J. Silver, 42, becomes CFO and principal financial and accounting officer effective October 19, 2026; he has been SVP, Finance since January 2025 and joined the company in October 2018.
- Silver's employment agreement sets an annual salary of $515,000, a target bonus of 45% of base salary, and a one-time grant of 25,000 restricted stock units vesting on the second anniversary of the grant date.
- Raju Prasad, Ph.D. resigned as CFO; he is expected to remain employed until a date on or before November 30, 2026.
- Under the agreement, termination without Cause or resignation for Good Reason carries a six-month notice period, extended to 12 months if it occurs within 12 months after a Change in Control.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.